Accordingly, Ajona et al. have recently demonstrated that both genetic and pharmacological inhibition of the IGF-1/IGF-1R axis enhance the antitumor activity of anti-PD-1–PD-L1 antibodies against lung cancer [16]. The gene discussed is CD274; the disease is lung carcinoma.